







208Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                
Catatonia in Anti-N-Methyl-D-Aspartate (NMDA) 
Receptor Encephalitis Misdiagnosed as Schizophrenia
Catatonia em Encefalite Anti-Receptor N-Metil-D- 
-Aspartato (NMDA) Confundida com Esquizofrenia
André PONTE1,2, Ana BRITO3, Camila NÓBREGA1, Sofia PINHEIRO3, João GAMA MARQUES1,2
Acta Med Port 2020 Mar;33(3):208-211  ▪  https://doi.org/10.20344/amp.11077
1. Hospital Júlio de Matos. Centro Hospitalar Psiquiátrico de Lisboa. Lisboa. Portugal.
2. Clínica Universitária de Psiquiatria e Psicologia Médica. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.
3. Hospital Santo António dos Capuchos. Centro Hospitalar Lisboa Central. Lisboa. Portugal.
 Autor correspondente: André Ponte. andredbponte@gmail.com
Recebido: 16 de julho de 2018 – Aceite: 10 de abril de 2019 | Copyright © Ordem dos Médicos 2019
ABSTRACT
Anti-N-Mmethyl-D-aspartate receptor encephalitis is an autoimmune disease of the central nervous system with prominent neurologic 
and psychiatric features. Symptoms appear progressively and sometimes with an exclusively psychiatric initial presentation. The pa-
tient’s evaluation should be meticulous, and we should use all the diagnostic tests required for the exclusion of entities that can mimic 
this disease. We report the diagnostic investigation of a case of anti-N-methyl-D-aspartate receptor encephalitis in a patient with a 
previous diagnosis of schizophrenia with poor response to antipsychotics. The aim of this case report is to highlight the importance of 
close surveillance for neuropsychiatric symptoms, especially catatonia, and to recognize autoimmune encephalitis in the differential 
diagnosis of psychotic disorders with neurological symptoms and resistance or intolerance to antipsychotics. A prompt diagnosis will 
contribute to a faster onset of therapy and an overall improvement in prognosis.
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RESUMO
A encefalite anti-receptor N-metil-D-aspartato é uma doença auto-imune do sistema nervoso central com características neurológicas 
e psiquiátricas proeminentes. Os sintomas surgem progressivamente e por vezes com uma apresentação inicial exclusivamente psi-
quiátrica. A avaliação do doente deve ser meticulosa e devem ser realizados todos os meios complementares de diagnóstico necessá-
rios à exclusão das entidades que podem mimetizar aquela patologia. Apresenta-se a evolução diagnóstica de um caso de encefalite 
anti-receptor N-metil-D-aspartato num doente com diagnóstico prévio de esquizofrenia sem resposta à terapêutica anti-psicótica. 
Pretende-se com este caso realçar a importância de uma vigilância apertada para sintomas neuropsiquiátricos, especialmente no caso 
de catatonia, e de ter em consideração as encefalites auto-imunes no diagnóstico diferencial de quadros psicóticos associados a sin-
tomas neurológicos e resistência ou intolerância a anti-psicóticos. Um diagnóstico célere contribuirá para a instituição de terapêutica 
atempadamente e uma melhoria global do prognóstico.
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INTRODUCTION
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) 
encephalitis is a treatable autoimmune disease of the cen-
tral nervous system with prominent neuropsychiatric fea-
tures.1 Patients develop progressive symptoms ranging 
from memory deficits, seizures and psychosis, to autonom-
ic and breathing instability and potentially lethal catatonia.2 
As patients with anti-NMDAR encephalitis are often initially 
evaluated by psychiatrists, it is very important that all cli-
nicians are aware of this clinical entity when attending to 
patients with psychotic disorders. We report the diagnostic 
investigation of a case of anti-NMDAR encephalitis in a cat-
atonic patient with poor response to antipsychotics and ben-
zodiazepines and a previous diagnosis of schizophrenia.
CASE REPORT
A 27-year-old white male was diagnosed with schizo-
phrenia after a clinical presentation of loosely structured 
persecutory delusions and auditory hallucinations. One 
year later, he was lost to follow-up, but was apparently 
asymptomatic and was not taking any medication. 
Six years later, the patient made three visits to the 
Emergency department in a single week with persistent 
headaches, nausea and vomiting. Two brain computed 
tomography (CT) scans showed no changes and he was 
discharged with symptomatic treatment. Three days later, 
he presented auditory hallucinations, persecutory delu-
sions, insomnia and psychomotor agitation. His urine toxi-
cology was positive for cannabinoids, without other relevant 
laboratory findings. He had a background of drug abuse but 
there was no other personal or family history.
He was admitted to our psychiatric ward with the diag-
nostic hypothesis of substance-induced psychosis versus 
schizophrenia. He started treatment with haloperidol and 
began to manifest fluctuating catatonic symptoms with 
periods of adequate behavior alternating with mutism, 
negativism and rigidity with waxy flexibility (the patient’s 
limbs retained their position for a sustained period after the 
examiner moved them, even in strange uncomfortable posi-
tions). The neurologic examination revealed reduction in 
speech volume and slowness of speech, generalized rigid-
ity with dorsal and cervical dystonia (in sustained flexion) 
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Figure 1 – Progression of neuropsychiatric symptoms in our patient
avoid neuroleptic malignant syndrome, and lorazepam was 
introduced, without success. There was a clinical deteriora-
tion with dysautonomic features, respiratory instability and 
generalized tonic-clonic seizure (Fig. 1). Post-ictal observa-
tion revealed bilateral eye and limb myoclonus. Repeated 
electroencephalography (EEG) revealed diffuse theta-delta 
slowing (Fig. 2) and a brief electrographic seizure (Fig. 3). 
Cerebrospinal fluid (CSF) showed only mild lymphocytic 
pleocytosis. 
The patient was transferred to a Neurology ward with 
the diagnostic hypothesis of encephalitis of unknown aetiol-
ogy. A new CSF test showed normal cytochemistry and was 
negative for neurotropic viruses. The brain magnetic reso-
nance imaging (Fig. 4) scan showed a right fronto-opercular 
and temporal anterior lesion compatible with head trauma 
in probable relation with unattended epileptic seizures dur-
ing hospitalization in the psychiatric ward. Infections were 
excluded and an autoimmune study was performed: antinu-
clear antibodies (ANA) and anti-ganglioside, anti-sulfatide, 
anti-neuronal, anti-myelin-associated glycoprotein (anti-
MAG), anti-glutamic acid decarboxylase (anti-GAD), anti-
contactin-associated protein-like 2 (anti-CASPR2), anti-
voltage-gated potassium channel (anti-VGKC) complex 
and anti-NMDAR antibodies. The CT scan of the cervical 
spine, chest, abdomen and pelvis scan, scrotal ultrasound, 
dermatologic and cavum examinations were all normal so 
an occult neoplasm was excluded.
Treatment with valproic acid, quetiapine and lorazepam 
in high doses showed some clinical improvement. 
One month later, positive anti-NMDAR antibodies were 
detected in the CSF and the diagnosis of anti-NMDAR 
encephalitis was confirmed. The patient was treated for five 
days with high-dose intravenous (IV) corticosteroids (meth-
ylprednisolone 1 g/day) followed by five more days of IV 
immunoglobulins (0.4 g/kg/day). He continued treatment 
with oral prednisolone 60 mg/day (20 days), then switched 
to a lower dose (50 mg/day for 36 days) and underwent 
monthly treatments with cyclophosphamide. 
Seven months after discharge, the neurological exami-
nation revealed bilateral postural tremor with myoclonic 
jerks and axial and limb rigidity that was more prominent 
on the left side; the neuropsychological evaluation revealed 
severe executive and memory deficits and puerile behaviour 
disturbance; a new brain MRI was performed that showed a 
partial resolution of the previously described lesions and a 
new search for anti-NMDAR antibodies in serum and CSF 
was negative. 
Three years after discharge, the patient has a normal 
neurological examination and showed a clear improvement 
in repeated neuropsychological assessment, revealing 
only a mild deficit in working memory and learning ability. 
Nowadays, he is only taking azathioprine 200 mg/day and 
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Figure 3 – EEG revealing the beginning of rhythmic electrographic activity in the F7, T3 and T5 leads, interpreted as a brief electrographic 
seizure. Patient awake with no clinical manifestation.




Isolated psychiatric episodes can occur as initial onset 
or relapse of anti-NMDAR encephalitis in about 4% of 
patients and those with milder presentations do not nec-
essarily progress to more severe multi-symptom disease, 
despite prolonged periods without treatment.3
In the present case, our patient had a psychotic epi-
sode at the age of 27 and although anti-NMDAR antibodies 
were not tested at the time, we propose that his earlier epi-
sode may have represented a limited presentation of the 
anti-NMDA receptor encephalitis, as has been previously 
described by other authors.4 
Since evidence suggest that early treatment improves 
outcomes,5 an approach based on conventional clinical 
assessment6 would allow the initiation of preliminary treat-
ment while other studies and comprehensive antibody 
tests are processed and later used to refine the diagnosis 
and treatment. We speculate that if we had followed this 
approach a better outcome could have been attained. 
A pattern that may start with a flu-like prodrome, fol-
lowed by psychiatric symptoms, seizures and movement 
disorders and autonomic instability later, along with resist-
ance or intolerance to antipsychotics, should always raise 
the suspicion of autoimmune encephalitis. We hope that 
this case highlights the importance of close surveillance for 
neuropsychiatric symptoms.
On the other hand, although only a minority of patients 
with psychosis are anti-NMDA receptor antibody positive, it 
remains to be established whether this subset of patients 
differs from antibody-negative patients in terms of underly-
ing disease and response to antipsychotic treatment.7 The 
anti-NMDA receptors are a new piece in the puzzle of schiz-
ophrenia,8 and more research is needed in order to clarify it.
All patients presenting with catatonic symptoms, even 
with a psychiatric or drug abuse history, deserve a careful 
examination to discard an eventual neurological cause.
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